The abstract is read at the publisher; the summary is JClub's.
In the HoFH International Clinical Collaborators (HICC) registry, untreated LDL-C in 950+ individuals from 45 countries is extremely high (median 14.7 mmol/L), with only 4% reaching guideline goals.
- Why it matters: Observational evidence for homozygous familial hypercholesterolaemia is scarce globally, limiting understanding of real-world care gaps and outcomes, including cardiovascular burden and access disparities.
- What they did: The HICC registry (NCT04815005) collected routine clinical and patient-reported data from over 950 HoFH individuals across 45 countries, reporting diagnosis timing, LDL-C levels, treatment use, and ASCVD status.
- The result: At diagnosis, 9% already had ASCVD or (supra)aortic valve disease, and early lipoprotein-apheresis was associated with greater LDL-C reductions and delayed ASCVD onset, while median age at death was 37 years (20–50).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.